NeoGenomics (NASDAQ: NEO)
Key Data Points
NeoGenomics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
NeoGenomics Company Info
NeoGenomics is a provider of genetic testing, specializing in cancer diagnostics.
News & Analysis
Why Shares of NeoGenomics Jumped Today
The company released promising full-year and fourth-quarter numbers.
Why Shares of NeoGenomics Jumped 53.9% This Week
The cancer screening company showed its turnaround may be working.
3 Top Small-Cap Stocks to Buy Right Now
These under-the-radar names deserve investors' attention.
NeoGenomics Slumps in Q2 but Readies for Second-Half Rebound
The oncology reference lab never stopped investing in near- and long-term opportunities. It expects that to pay off -- and soon.
3 Top Healthcare Stocks to Buy Right Now
These pioneers will be winners however the pandemic plays out.
2 Stocks to Buy and Hold for Decades
Near-term headwinds won’t damage the long-term prospects of these two companies.
The Coronavirus Pandemic Will Test Invitae's Telemedicine Ambitions
Invitae wants to provide medical-grade genetic testing to the masses. Is the business ready for the first big test?
Here's Why NeoGenomics Is Tumbling Today
The company decided to pull the trigger on a combined offering of stock and debt to pad its balance sheet during uncertain times.
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.